Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 53 citing articles:

Postacute sequelae of COVID-19 at 2 years
Benjamin Bowe, Yan Xie, Ziyad Al‐Aly
Nature Medicine (2023) Vol. 29, Iss. 9, pp. 2347-2357
Open Access | Times Cited: 213
Long COVID science, research and policy
Ziyad Al‐Aly, Hannah Davis, Lisa McCorkell, et al.
Nature Medicine (2024) Vol. 30, Iss. 8, pp. 2148-2164
Open Access | Times Cited: 79
Mapping the effectiveness and risks of GLP-1 receptor agonists
Yan Xie, Taeyoung Choi, Ziyad Al‐Aly
Nature Medicine (2025)
Closed Access | Times Cited: 5
Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission
Liang En Wee, An Ting Tay, Calvin J. Chiew, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 10, pp. 1328-1333
Open Access | Times Cited: 26
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
Stefanie Reis, Maria‐Inti Metzendorf, Rebecca Kuehn, et al.
Cochrane library (2023) Vol. 2023, Iss. 11
Open Access | Times Cited: 22
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study
Zhiguo Zhou, He Zheng, Gui’e Xiao, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Methodological challenges using routine clinical care data for real-world evidence: a rapid review utilizing a systematic literature search and focus group discussion
Michelle Pfaffenlehner, Max Behrens, Daniela Zöller, et al.
BMC Medical Research Methodology (2025) Vol. 25, Iss. 1
Open Access
Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C
Abhishek Bhatia, Alexander Preiss, Xuya Xiao, et al.
PLoS Medicine (2025) Vol. 22, Iss. 1, pp. e1004493-e1004493
Open Access
Effectiveness and Safety of Oral Azvudine for Elderly Hospitalized Patients With COVID‐19: A Multicenter, Retrospective, Real‐World Study
Ranran Sun, Haiyu Wang, Junyi Sun, et al.
Advanced Science (2025)
Open Access
Prevention of long COVID: progress and challenges
Ziyad Al‐Aly
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 7, pp. 776-777
Open Access | Times Cited: 13
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Carlos King Ho Wong, Jonathan J. Lau, Ivan Chi Ho Au, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
Yonatan Moges Mesfin, Joseph E. Blais, Kelemu Tilahun Kibret, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 9, pp. 2119-2131
Open Access | Times Cited: 4
Pathogenic mechanisms of cardiovascular damage in COVID-19
Honghua Shao, Rui‐Xing Yin
Molecular Medicine (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 3
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
Sien Ombelet, Diego Castanares‐Zapatero, Fabian Desimpel, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 2
Open Access | Times Cited: 2
Nationwide Target Trial Emulation Evaluating the Clinical Effectiveness of Oral Antivirals for COVID-19 in Korea
Kyungmin Huh, Youngji Jo, Gi Hwan Bae, et al.
Journal of Korean Medical Science (2024) Vol. 39, Iss. 42
Open Access | Times Cited: 2
Nirmatrelvir/ritonavir for the treatment of immunocompromised adult patients with early‐stage symptomatic COVID‐19: A real‐life experience
José María Caso, Mario Fernández‐Ruiz, Francisco López‐Medrano, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 9
Open Access | Times Cited: 7
Azvudine and nirmatrelvir–ritonavir in hospitalized patients with moderate‐to‐severe COVID‐19: Emulation of a randomized target trial
Yiling Zhou, Yi Liu, Li Jiang, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 12
Open Access | Times Cited: 7
Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
Ioannis Karniadakis, Nikolaos Mazonakis, Constantinos Tsioutis, et al.
Infectious Disease Reports (2023) Vol. 15, Iss. 6, pp. 662-678
Open Access | Times Cited: 6
Risk of severe coronavirus disease 2019 despite vaccination in patients requiring treatment with immune‐suppressive drugs: A nationwide cohort study of US Veterans
Sonia T. Anand, Austin D. Vo, Jennifer La, et al.
Transplant Infectious Disease (2023) Vol. 26, Iss. 1
Closed Access | Times Cited: 5
Mismanagement of SARS-CoV-2 Infection Pre Hospitalisation during the Omicron Era: Antibiotics and Steroids Instead of Early Antivirals
Andrea Giacomelli, Cosmin Lucian Ciubotariu, Martina Zacheo, et al.
Viruses (2024) Vol. 16, Iss. 7, pp. 1005-1005
Open Access | Times Cited: 1
Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions
Abby E. Rudolph, Farid Khan, Tanya Singh, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 9, pp. 2035-2052
Open Access | Times Cited: 1
Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort Study
Adeel A. Butt, Yan Peng, Obaid S. Shaikh, et al.
The Journal of Infectious Diseases (2023) Vol. 229, Iss. 1, pp. 147-154
Open Access | Times Cited: 4
The impact of vaccination and outpatient treatment on the economic burden of Covid-19 in the United States omicron era: a systematic literature review
Vicki Pierre, Florin Draica, Manuela Di Fusco, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 1519-1531
Open Access | Times Cited: 3
Making causal inferences from transactional data: A narrative review of opportunities and challenges when implementing the target trial framework
Santiago Esteban, Alejandro G. Szmulewicz
Journal of International Medical Research (2024) Vol. 52, Iss. 3
Open Access
Page 1 - Next Page

Scroll to top